Pharma Mar SA 2015 SR
The report highlights the 2015 activities of PharmaMar Group, following its reverse merger with Zeltia. Key developments include the FDA and Japanese approval of Yondelis for soft tissue sarcoma and the progression of clinical trials for Aplidin and PM1183. The company demonstrated a strong commitment to R&D, investing significantly more per employee than the Spanish average. Environmental management was a priority, with ISO 14001 certifications maintained for major subsidiaries and the promotion of the eco-friendly Xylazel Aire Sano paint line. Social initiatives focused on employee welfare, workplace safety, and community support through scientific scholarships and partnerships with patient associations.
Company: Pharma Mar SA
Sector: Manufacturing
Country: Spain
Year: 2015
Type: SR
Pages: 110
Pharma Mar SA
The report highlights the 2015 activities of PharmaMar Group, following its reverse merger with Zeltia. Key developments include the FDA and Japanese approval of Yondelis for soft tissue sarcoma and the progression of clinical trials for Aplidin and PM1183. The company demonstrated a strong commitment to R&D, investing significantly more per employee than the Spanish average. Environmental management was a priority, with ISO 14001 certifications maintained for major subsidiaries and the promotion of the eco-friendly Xylazel Aire Sano paint line. Social initiatives focused on employee welfare, workplace safety, and community support through scientific scholarships and partnerships with patient associations.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2015
Reporting Period
Jan 1, 2015 - Dec 31, 2015
Fiscal Year
2015
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Other Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Water Consumption
Women on Board
Women in Management
Employees